2023-10-18 14:16:35
Oncology and Laboratory Medicine are two branches of medicine that work in a coordinated manner to address the cancer patient. The Clinical Laboratory can help identify very specific mutations in tumors, so that it is possible to select the best therapeutic target for each patient. Likewise, it is key in determining the best immunotherapy treatment and in knowing the predisposition to hereditary cancer. These are some of the main topics of interest that are addressed at the XVII National Congress of Clinical Laboratory (LABCLIN 2023), which is held from October 18 to 20 in Zaragoza and is organized by the Spanish Society of Laboratory Medicine (SEQCML). ), the Spanish Association of Medical Biopathology (AEBM-ML) and the Spanish Association of Clinical Laboratory (AEFA).
One of the main novelties of the congress, which has received some 1,200 communications, is the celebration of different symposiums, debate tables and scientific activities organized by each of the scientific societies. Specifically, in the symposium, “Tumor markers in the face of new challenges in personalized oncology”, moderated by the member of the SEQCML Cancer Biological Markers Commission, Dr. Álvaro González Hernández, the importance of the Clinical Laboratory in the management of the oncological patient. His work makes possible, for example, the search for biomarkers in immunotherapy. “It allows us to choose the best antibody, monitor the response and also see its evolution. Given that, sometimes, these therapies can cause adverse effects and analytical control of all these processes is necessary,” indicates Dr. Álvaro González Hernández.
In this sense, the use of analytical tools allows the determination of mutations through liquid biopsy in cancer patients to choose the best therapeutic target at certain times. This is how Dr. Álvaro González Hernández explains it: “If you are treating a patient with lung cancer with a medication that is sensitive to that drug, over time, cells that are resistant to that drug may appear and end up being predominant. ”. In this way, as the SEQCML member points out, “you need the necessary analytical tools to be able to identify that resistant cell and attack them specifically.”
The Clinical Laboratory is also key in the interpretation of genetic studies of predisposition to hereditary cancer. As Dr. Álvaro González Hernández highlights, this interpretation is within the reach of the patient, so that he “can know his risks of suffering from cancer through genetic counseling.”
The interrelation between Oncology and the Clinical Laboratory is increasingly intense. “Nowadays, for example, in many tumor committees the participation of a person from the laboratory is necessary to guide and help in these fields. However, Clinical Laboratory specialists must be prepared and have sufficient knowledge to provide a response to this demand,” concludes Dr. Álvaro González Hernández.
Residents of the Clinical Laboratory – SEQC
https://www.linkedin.com/company/seqc-ml/
Fuente: BERBES
1697639077
#Laboratory #Medicine #key #choosing #therapeutic #target #cancer #patients
